Trial Profile
A Randomized, Single Center, Double Blind, Two Treatment, Two-Period, Crossover Glucose Clamp Study To Test For Bioequivalence Between Wockhardtâ??s Consegnaâ?¢ - 30/70 (Bi Phasic Isophane Insulin 30/70 Injection 200 IU) and Mixtard® 30/70 (100 IU), In Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Insulin-lispro/Insulin-suspension-isophane (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Wockhardt Ltd
- 10 Jan 2020 Status changed from recruiting to completed.
- 26 Mar 2018 Status changed from not yet recruiting to recruiting.
- 15 Dec 2017 New trial record